Welcome to our dedicated page for PNTM.WS news (Ticker: PNTM.WS), a resource for investors and traders seeking the latest updates and insights on PNTM.WS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PNTM.WS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PNTM.WS's position in the market.
Pontem Corporation announced the closing of its upsized initial public offering (IPO) on January 19, 2021, raising $690 million. The offering comprised 60 million units priced at $10.00 per unit, with an additional 9 million units sold due to the underwriters' over-allotment option. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. The securities will trade under the symbols PNTM for shares and PNTM.WS for warrants. Credit Suisse and Guggenheim acted as joint book-running managers for the offering.
